The Pharmacy Compounding Advisory Committee (PCAC) is the FDA committee that votes on which substances belong on the Section 503A bulk drug substances list and where they sit (Category 1, 2, or 3). It is the formal venue where research-peptide policy gets made.
The July 23-24, 2026 peptide session at FDA's White Oak Campus in Silver Spring, Maryland (docket FDA-2025-N-6895) is the most consequential PCAC meeting in the site's coverage window. The two-day tally: 6 of 7 peptides recommended for 503A. Day 1 (July 23) cleared all four peptides on the docket: BPC-157 (8-6 with 1 abstention), KPV (8-6 with 1 abstention), TB-500 (8-6), and MOTS-c (7-5 with 2 abstentions). Day 2 (July 24) recommended Semax 8-5 for cerebral ischemia, migraine, and trigeminal neuralgia, recommended Epitalon 7-4 for insomnia, and narrowly rejected Emideltide (delta sleep-inducing peptide, DSIP) — the sole no vote of the two-day session. Every one of the 6 wins overrode the FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides, citing immunogenicity, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use.
Panel composition shaped the outcome. The FDA named eight new PCAC members on June 29 to fill the peptide-session seats; at least seven have documented ties to peptide-related businesses per STAT News reporting, including Tennessee state senator Bobby Harshbarger and clinicians who run high-price peptide consultations. Time Magazine framed the vote as 'an FDA committee voting in favor of peptides despite the agency's opposition.' PCAC recommendations are advisory, not binding; formal FDA rulemaking to add a substance takes approximately 6 to 18 months. Stories here cover meeting minutes, vote outcomes, public comments, and the petitions that drive new substances onto the agenda. See [[503a-bulks-list]] and [[fda-pcac]] for adjacent threads.
US News, syndicating an Associated Press wire story, published a piece Wednesday July 1, 2026 titled 'FDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panel,' continuing the mainstream-media coverage of the FDA career-staff briefing documents that landed Monday-Tuesday June 29-30. The AP framing tied together two threads that STAT News, NBC News, NPR, Washington Post, PBS NewsHour, and CNN had covered separately: the substantive staff position that none of the seven peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence for 503A bulks list eligibility; and the parallel panel-composition story flagging that at least seven of the eight new PCAC panelists named Monday have ties to peptide-related businesses and clinics. The AP wire distribution amplifies the story to hundreds of regional papers and broadcast outlets, extending public awareness well beyond the health-policy audience that read the original STAT scoop. Public Citizen's July 'Outrage of the Month' column, BioCentury's industry-analyst piece, and Personal Care Insights coverage each add to the growing critic chorus three weeks before the July 23-24 PCAC vote.
Public Citizen, the consumer advocacy organization founded by Ralph Nader in 1971, published its July 2026 'Outrage of the Month' column titled 'The FDA, Peptides and RFK Jr.' The piece argues that when the FDA banned compounding of nineteen peptides in 2023, it cited immunogenicity risks for certain routes of administration, impurity concerns, and lack of sufficient information to know whether the drugs would cause harm when administered to humans. The advocacy position: 'There is no credible reason to believe that peptides deemed unproven or unsafe in 2023 are now miraculously safe and effective.' Public Citizen also raised concerns about the eight new PCAC panelists named Monday June 29, warning that the committee could be filled with members who would 'rubber stamp Kennedy's wishes' rather than substantively review the FDA staff briefing documents concluding the seven peptides have insufficient evidence for 503A bulks list eligibility. The piece adds to a June-July critic chorus that includes STAT News (panelist conflicts), NBC News + NPR + Washington Post (FDA scientists disagree with RFK Jr.), and BioCentury (peptide deregulation threatens drug-safety foundations).
BioCentury, the pharma-industry analyst publication, published a piece late in the week of June 29 arguing that HHS Secretary RFK Jr.'s peptide deregulation push threatens the foundations of drug safety. The industry-analyst framing adds to the growing critic chorus documenting concerns about the July 23-24 PCAC vote: FDA career-staff briefing documents concluding all seven peptides have insufficient evidence; STAT News' scoop on the panel-composition changes and conflicts of interest; NBC News, NPR, and Washington Post coverage of the FDA-staff-versus-RFK-Jr. tension; and Public Citizen's July 'Outrage of the Month' advocacy position. The specific BioCentury argument is that the drug-safety framework depends on FDA's ability to defer to career scientific staff on safety and evidence questions; a political override of the staff position (via new panelist composition or via FDA acceptance of a panel vote against staff) would establish a precedent applicable well beyond the seven peptides under immediate review. Additional voices: Personal Care Insights framed the deregulation as 'amid safety concern backlash'; the AP characterized the panel composition as a shift from 'academics and researchers' to 'health professionals who prescribe, produce or promote peptides.'
FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.
STAT News reporter Lizzy Lawrence broke a scoop late Monday June 29, 2026 disclosing that the FDA on Monday published the names of eight new panelists who will serve on the July 23-24 Pharmacy Compounding Advisory Committee reviewing seven peptides for 503A bulks list eligibility. The majority of new members are involved with businesses that promote and prescribe peptides, meaning they will be weighing rules changes that could materially benefit them. Specific named members include Bobby Harshbarger, a pharmacist and Tennessee state senator whose mother Rep. Diana Harshbarger (R-TN) is also a pharmacist and has formally urged Kennedy to convene the panel; and Dr. Gabriel Alizaidy, who charges $500 for 'peptide and hormone' consultations that include advice on 'where to safely get each peptide or compound.' UC Davis cell-biology professor Paul Knoepfler told STAT: 'It's concerning that several members of the newly formulated [committee] appear to sell unproven offerings including stem cells and peptides, sometimes both.' FDA rules permit experts with financial stakes to serve on advisory panels as long as the relationship is disclosed and the agency explains why the expertise outweighs the potential conflict. Parallel coverage ran in CNN, PBS NewsHour, Washington Times, and CP24.
The Washington Post published a synthesis-explainer piece on June 30, 2026 titled 'Peptides are popular and controversial. Why?' walking consumers through the regulatory tension that has built up over the past month between HHS Secretary RFK Jr.'s public push to expand peptide access and FDA career-scientist briefing documents concluding the evidence is insufficient. The piece sits alongside the Post's parallel reporting (also June 30) titled 'RFK Jr.'s plan to boost peptide access just got more complicated' which framed the FDA staff recommendation as a substantive challenge to the Secretary's agenda. The two Post pieces target different audiences: the first is a consumer explainer (what peptides are, why wellness influencers tout them, what BPC-157 / TB-500 / MOTS-c actually do); the second is a politics-of-policy piece for the regulatory-and-policy audience. Both pieces frame the July 23-24 PCAC meeting as the substantive decision point, while the broader peptide-cultural-moment that the wellness market and STAT, NBC, and NPR coverage have all flagged forms the backdrop. The Washington Times, CNN, and PBS NewsHour ran adjacent coverage.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 closed at the end of business Tuesday June 30, 2026. Individuals or organizations who wanted to give a formal oral presentation at the public-comment portion of the meeting had to notify FDA by today with a brief description of the evidence or arguments to be presented, names and addresses of participants, in-person versus virtual preference, and a requested time allotment. Written comments to docket FDA-2025-N-6895 at regulations.gov remain open through July 9, 2026 for formal provision to PCAC members ahead of the meeting; the hard deadline for all written comments is July 22, 2026 at 11:59 PM ET. The two-day meeting at FDA's White Oak campus in Silver Spring, Maryland (with virtual attendance option) reviews seven peptides for 503A bulks list eligibility: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Oral-testimony filers will face the FDA career-staff briefing documents released this week concluding the evidence is insufficient on all seven substances.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.
Dr. Catherine Varney, the University of Virginia Health Obesity Medicine Director, gave WSET (Roanoke-Lynchburg ABC affiliate) a syndicated local-TV interview published June 25, 2026 walking through the clinical realities of the unregulated peptide market. Her position on BPC-157 and TB-500 (both under FDA Pharmacy Compounding Advisory Committee review on July 23, 2026): animal-study evidence shows promise, while human clinical evidence remains thin, and she will not prescribe them. The interview frames the distinction patients often miss: FDA-approved weight-loss medications such as Ozempic and Wegovy are synthetic GLP-1 receptor agonists with rigorous Phase 3 evidence and post-marketing safety surveillance, while BPC-157, TB-500, and the broader unregulated stack are research-chemical products with no completed Phase 3 trial in any human indication. Varney's quoted position: 'I will not prescribe them.' She added that she will instead monitor patients who choose to take them, watch their labs for adverse effects, and emphasize lifestyle interventions with long-standing evidence (eating better and exercising more). The story sits inside a broader pattern of academic-medical-center clinicians publishing consumer-facing warnings ahead of PCAC.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
Bloomberg Businessweek published a long-form feature June 17 mapping the peptide gold rush as black-market wellness drugs move toward legitimacy ahead of the July 23-24 PCAC meeting. The piece centers on Janoshik Analytical, a Prague-based purity-testing operation that grew its peptide test volume by more than 1,200% from 2023 to 2025 and reports almost nine figures in annual revenue. Investor estimates put the current US black market at $1-3 billion. Bloomberg reports peptides are now being pitched to menopausal suburban moms and offered at med spas as a casual add-on to Botox, with FDA-regulated peptide pricing strategy now an active question for entrepreneurs, investors, and incumbents alike.
A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.